Innovent Biologics (1801) Price & Analysis

Compare

16 Followers

1801 Stock Chart & Stats

Day’s Range― - ―

52-Week RangeHK$28.65 - HK$91.70

Previous CloseN/A

Volume9.75M

Average Volume (3M)25.74M

Market Cap

$152.22B

Enterprise ValueHK$124.89B

Total Cash (Recent Filing)$7.88B

Total Debt (Recent Filing)¥2.83B

Price to Earnings (P/E)―

Beta0.98

Next Earnings

Aug 27, 2025

EPS Estimate

0.14

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.20

Shares Outstanding1,709,431,300

10 Day Avg. Volume19,239,499

30 Day Avg. Volume25,739,477

Financial Highlights & Ratios

PEG Ratio-14.93

Price to Book (P/B)9.97

Price to Sales (P/S)0.00

P/FCF Ratio-141.57

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$92.26

Price Target Upside3.60% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

Innovent Biologics News

PremiumThe Fly

Innovent Biologics announces multiple mechanism-of-action analyses of mazdutide

28d ago

PremiumRatings

Innovent Biologics: Promising Pipeline and Strategic Focus Drive Buy Rating

12d ago

PremiumCompany Announcements

Innovent Biologics Completes HK$4.27 Billion Share Placement

17d ago

PremiumCompany Announcements

Innovent Biologics Grants Share Options and Restricted Shares to Employees

21d ago

PremiumCompany Announcements

Innovent Biologics’ Mazdutide Approved for Weight Management in China

24d ago

PremiumCompany Announcements

Innovent Biologics Announces New Share Placement

25d ago

PremiumCompany Announcements

Innovent Biologics Secures Shareholder Approval for Key Resolutions at AGM

26d ago

PremiumThe Fly

Innovent Biologics announces first participant dosed in Phase 3 GLORY-OSA

1M ago

See All HK:1801 News

See All News >

Bulls Say, Bears Say

Bulls Say

Financial PerformanceInnovent achieved profitability ahead of schedule, realizing better-than-expected profitability due to strong product revenue growth and one-off license fee income.

Product DevelopmentInnovent recently launched mazdutide, China’s first domestic dual-target GLP-1 drug for obesity, marking a significant milestone in its non-oncology portfolio.

Strategic GrowthInnovent holds a robust cash balance of RMB10.2bn, supporting its strategic initiatives and growth.

Bears Say

CompetitionThe potential of IBI3003 to compete with CAR-T therapies presents a significant opportunity within the oncology drug development sector.

Financials

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

―

Insiders

8.92%

Mutual Funds

― Other Institutional Investors

83.39% Public Companies and

Individual Investors

Detailed Ownership Overview >

1801 FAQ

What was Innovent Biologics’s price range in the past 12 months?

Innovent Biologics lowest stock price was HK$28.65 and its highest was HK$91.70 in the past 12 months.

What is Innovent Biologics’s market cap?

Innovent Biologics’s market cap is $152.22B.

When is Innovent Biologics’s upcoming earnings report date?

Innovent Biologics’s upcoming earnings report date is Aug 27, 2025 which is in 37 days.

How were Innovent Biologics’s earnings last quarter?

Innovent Biologics released its earnings results on Mar 26, 2025. The company reported HK$0.197 earnings per share for the quarter, beating the consensus estimate of -HK$0.251 by HK$0.448.

Is Innovent Biologics overvalued?

According to Wall Street analysts Innovent Biologics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Innovent Biologics pay dividends?

Innovent Biologics does not currently pay dividends.

What is Innovent Biologics’s EPS estimate?

Innovent Biologics’s EPS estimate is 0.14.

How many shares outstanding does Innovent Biologics have?

Innovent Biologics has 1,709,431,300 shares outstanding.

What happened to Innovent Biologics’s price movement after its last earnings report?

Innovent Biologics reported an EPS of HK$0.197 in its last earnings report, beating expectations of -HK$0.251. Following the earnings report the stock price went down -0.255%.

Which hedge fund is a major shareholder of Innovent Biologics?

Currently, no hedge funds are holding shares in HK:1801

Innovent Biologics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-0.72%

Trailing 12-Months

Asset Growth

1.76%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Innovent Biologics

Innovent Biologics, Inc. (1801) is a leading biopharmaceutical company based in China, focused on the development, manufacture, and commercialization of innovative and high-quality biologic therapies. The company primarily operates in the biotechnology and pharmaceutical sectors, with a strong emphasis on oncology, metabolic, autoimmune, and other major disease areas. Innovent's core products include a portfolio of monoclonal antibodies and biologics addressing some of the most challenging health conditions.

1801 Stock 12 Month Forecast

Average Price Target

HK$92.26

▲(3.60%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"31":"HK$31","70":"HK$70","109":"HK$109","50.5":"HK$50.5","89.5":"HK$89.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":108.40000003182624,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$108.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":92.255554188,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$92.26</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":66.0000000193776,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$66.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[31,50.5,70,89.5,109],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,78.4,80.70769231014049,83.01538462028097,85.32307693042145,87.63076924056192,89.9384615507024,92.24615386084288,94.55384617098336,96.86153848112384,99.16923079126431,101.4769231014048,103.78461541154527,106.09230772168576,{"y":108.40000003182624,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,78.4,79.46581186061539,80.53162372123077,81.59743558184616,82.66324744246154,83.72905930307692,84.7948711636923,85.8606830243077,86.92649488492309,87.99230674553847,89.05811860615385,90.12393046676924,91.18974232738462,{"y":92.255554188,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,78.4,77.44615384764444,76.49230769528887,75.53846154293329,74.58461539057772,73.63076923822216,72.67692308586659,71.72307693351101,70.76923078115544,69.81538462879988,68.86153847644431,67.90769232408873,66.95384617173316,{"y":66.0000000193776,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":35.2,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.4,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.95,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.1,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.05,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.65,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.6,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.75,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.45,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.85,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.75,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.1,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.4,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >